Portal de Periódicos da CAPES

Early Insight into Mitralign Direct Annuloplasty for Treatment of Functional Mitral Regurgitation

2011; Volume: 6; Issue: 2 Linguagem: Inglês

10.15420/icr.2011.6.2.170

1756-1477

Lazar Mandinov, Lutz Büllesfeld, Kuck Karl-Heinz, Eberhard Grube,

Infective Endocarditis Diagnosis and Management

The Mitralign system (Mitralign, Inc., Tewksbury, Massachusetts, US) is a set of devices approaching the posterior mitral annulus through the left ventricle (LV). Two pairs of surgical pledgets are delivered at the P1 and P3 site of the annulus. The paired pledgets are pulled together to decrease the annulus circumference, and the achieved plication is locked in place. In swine hearts the permanent implants, pledgets and locks, lack any adverse pathology such as necrosis, thrombosis, haemorrhage, mineralisation or exuberant inflammation, and the overall tissue response at 30-day follow-up is considered benign. The clinical experience is limited to a few patients enrolled in a first-in-man study. In a perfect candidate with relatively preserved LV function, moderately enlarged ventricle and limited leaflet tethering, Mitralign annuloplasty may reduce mitral regurgitation significantly from grade 4+ to grade 1+. More research and clinical trials are needed to understand this novel technique for percutaneous mitral valve repair.